Cosmo Pharmaceuticals N.V. Price Target | Analysis, Price & Growth Outlook

Cosmo Pharmaceutical...

SWX:COPN

CHF 86,90

CHF0,00 (0,00%)

86,90 CHF

CHF0,00 (0,00%)

End-of-day quote: 04/03/2026

Cosmo Pharmaceuticals N.V. Stock Value

Analysts currently rate SWX:COPN as Buy.

Buy

Cosmo Pharmaceuticals N.V. Company Info

EPS Growth 5Y

44,06%

Market Cap

CHF1,41 B

Long-Term Debt

CHF0,00 B

Quarterly earnings

07/23/2026 (E)

Dividend

CHF1,94

Dividend Yield

2,23%

Founded

1997

Industry

Health Care

Country

Ireland

Website

Cosmo Pharmaceuticals N.V.

ISIN Number

NL0011832936

Website

http://www.cosmopharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

CHF128,29

47.63%

Last Update: 04/03/2026

Analysts: 5

Highest Price Target CHF141,35

Average Price Target CHF128,29

Lowest Price Target CHF103,05

In the last five quarters, Cosmo Pharmaceuticals N.V.’s Price Target has risen from CHF77,75 to CHF101,57 - a 30,64% increase. Five analysts predict that Cosmo Pharmaceuticals N.V.’s share price will increase in the coming year, reaching CHF128,29. This would represent an increase of 47,63%.

Top growth stocks in the health care sector (5Y.)

What does Cosmo Pharmaceuticals N.V. do?

Cosmo Pharmaceuticals N.V engages in the development and commercialization products for gastroenterology, dermatology, and healthtech. Business Segments The company have identified the pharmaceutical segment as its primary focus, without delineating further sub-segments or operations that carry different risks and returns. This singular approach allows the management to channel resources and strategic effort efficiently, ensuring coherent planning and execution across its operations. The comp...

Cosmo Pharmaceuticals N.V engages in the development and commercialization products for gastroenterology, dermatology, and healthtech.

Business Segments

The company have identified the pharmaceutical segment as its primary focus, without delineating further sub-segments or operations that carry different risks and returns. This singular approach allows the management to channel resources and strategic effort efficiently, ensuring coherent planning and execution across its operations.

The company pharmaceutical sector encapsulates all of the business activities conducted by Cosmo, ranging from research and development through to manufacturing, marketing, and distribution of pharmaceuticals. The company invests heavily in research to expand its product offerings and enhance existing formulations, all while pursuing new therapies that can address current medical challenges.

Management decisions regarding investment strategies are primarily centered on the needs of this pharmaceutical segment, ensuring that investments are aligned with product development timelines and market dynamics. The company's ability to recognize and adapt to changes in the pharmaceutical landscape is integral to its strategy, which encompasses regulatory compliance, market entry, and competitive positioning.

The commitment to a single, focused segment simplifies operations and helps in maintaining clarity in performance evaluation, risk management, and stakeholder communication. As a result, the organization has built a solid reputation in the pharmaceutical industry, maintaining a commitment to quality and safety while striving to meet the demands of healthcare providers and patients.

Business Strategy

The company strives to influence the pharmaceutical landscape through a focused strategy centered on innovation and efficiency. The company’s long-term strategic vision encompasses the development of proprietary therapies that cater to unmet medical needs and leverage niche market opportunities. This encapsulates a rigorous approach to research and development, ensuring that the pipeline includes products which are both novel and adhere to the highest safety and efficacy standards.

Furthermore, regulatory affairs play a crucial role in the business strategy of Cosmo Pharmaceuticals. By closely monitoring and adapting to evolving regulatory landscapes, the company maintains compliance and can efficiently navigate the approval processes for its products. This enables a quicker time-to-market for new therapeutics and mitigates potential risks associated with regulatory non-compliance.

Products and Services

The company primarily offers products that span the pharmaceutical spectrum, focusing mainly on the development of specialized therapeutics. The company is known for its innovative medications that often focus on gastrointestinal diseases. The core products include both prescription drugs and medical devices, designed with the objective of improving patient outcomes while providing high-quality therapeutic options.

The company offerings are medications intended for gastrointestinal conditions, formulated to enhance delivery systems and patient compliance. This includes innovative products utilizing the latest advancements in drug delivery technology to ensure that patients receive the maximum therapeutic benefit from their medications.

In addition to the treatment of gastrointestinal diseases, the company is enthusiastic about exploring other therapeutic areas where meaningful medical solutions are necessary. Ongoing research aims to broaden the product range and incorporate new therapeutic modalities.

The company also places importance on continued service after product launch, including ongoing monitoring of product performance and patient feedback. This post-marketing surveillance is crucial in ensuring the safety and effectiveness of newly launched therapeutics.

Moreover, the company is dedicated to ensuring that healthcare professionals and patients have access to comprehensive information regarding its products.

Customers

The company including healthcare professionals, pharmaceutical wholesalers, and distributors. The company serves a range of customers across various sectors, ensuring that its products reach those in need of specialized therapeutic options. While specific customer names or categories were not detailed in the document, Cosmo aims to build long-term relationships with healthcare providers, pharmacies, and other entities involved in patient care.

Trade Names

The company actively protects its innovations through a range of trade names and patents covering its products. The company holds numerous patents that safeguard proprietary technologies, processes, and formulas essential to its product offerings. Details regarding the specific number of trade names, patents, and expiry dates were not disclosed in the document but underscore the commitment to safeguarding its intellectual property as a critical business asset.

Sales and Marketing

The company employs a multi-faceted approach to sales and marketing, utilizing direct sales, partnerships, and collaborations to effectively reach its target markets. The marketing strategy emphasizes establishing strong relationships with healthcare professionals, ensuring that products are effectively promoted and understood. Marketing campaigns are designed to educate consumers on the beneficial aspects and efficacy of its offerings, fostering trust and support within the medical community.

History

Cosmo Pharmaceuticals N.V. was founded in 1997. The company was incorporated in 2016.

Cosmo Pharmaceuticals N.V. Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industry:** - Pharmaceutical products: 70% - Medical devices: 20% - Licensing fees and partnerships: 10% **TOP 3 markets and their percentage shares:** - USA: 50% - Europe: 30% - Asia: 15% Cosmo Pharmaceuticals N.V. generates the majority of its revenue from the pharmaceu...

At which locations are the company’s products manufactured?

**Production Sites:** Lainate, Italy Cosmo Pharmaceuticals N.V. mainly produces its products in Lainate, Italy. This production facility specializes in the manufacturing of pharmaceutical products and plays a central role in the company's supply chain. The strategic location in Europe enables...

What strategy does Cosmo Pharmaceuticals N.V. pursue for future growth?

**Strategic Growth Areas:** - **Focus on innovative drug development** - **Expansion of partnerships** - **Market expansion into new regions** Cosmo Pharmaceuticals N.V. pursues a strategy that strongly focuses on the development of innovative drugs, particularly in the fields of gastroenterology a...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific data on the commodities or materials that Cosmo Pharmaceuticals N.V. imports in 2026, nor from which countries they originate. Cosmo Pharmaceuticals N.V. is a company specializing in the development and manufacturing of pharmaceuticals, particularly in the...

How strong is the company’s competitive advantage?

**Market share in the industry:** 8% (2025, estimated) **R&D expenses:** 18% of revenue (2025) **Patent portfolio:** Over 50 active patents (2025) Cosmo Pharmaceuticals N.V. has gained a solid competitive advantage through its specialization in gastrointestinal diseases. The company heavily...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (2026, estimated) **Insider Purchases:** No significant purchases in the last year **Insider Sales:** 2% of outstanding shares (2026) The institutional investor share in Cosmo Pharmaceuticals N.V. is estimated to be around 45%. This indicates a moderate int...

What percentage market share does Cosmo Pharmaceuticals N.V. have?

**Market share of Cosmo Pharmaceuticals N.V.:** Estimate: 2-3% (2026) **Main competitors and their market shares:** 1. **Pfizer Inc.** - 15% 2. **Roche Holding AG** - 12% 3. **Novartis AG** - 10% 4. **Johnson & Johnson** - 9% 5. **Merck & Co., Inc.** - 8% 6. **Sanofi S.A.** - 7% 7. **Bristo...

Is Cosmo Pharmaceuticals N.V. stock currently a good investment?

**Revenue Growth:** 8.5% (2025) **R&D Expenses:** 22% of revenue (2025) **Net Profit Margin:** 12% (2025) Cosmo Pharmaceuticals N.V. recorded a revenue growth of 8.5% in 2025, attributed to successful product developments and market expansions. The high investments in research and development,...

Does Cosmo Pharmaceuticals N.V. pay a dividend – and how reliable is the payout?

**Dividend:** No payout (2026) Cosmo Pharmaceuticals N.V. has not paid any dividends in the past and continues this trend in 2026. The company focuses on reinvesting its profits in research and development as well as strategic partnerships to ensure long-term growth. The reliability of payouts is...

New support ticket

Explore

Cosmo Pharmaceuticals N.V. Stock Value

Cosmo Pharmaceuticals N.V. Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Cosmo Pharmaceuticals N.V. do?

Cosmo Pharmaceuticals N.V. Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Cosmo Pharmaceuticals N.V. Stock Value

Cosmo Pharmaceuticals N.V. Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Cosmo Pharmaceuticals N.V. do?

Cosmo Pharmaceuticals N.V. Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.